These findings suggest a potential concept that metformin has dual effects on VEGF signaling-mediated tumor angiogenesis: on one hand, metformin decreases the secretion of VEGF from tumor cells by targeting HER2 signaling; on the other hand, metformin has the inhibitory effects on VEGF signaling. Here, VEGFA is linked to neoplasm.